Aclarion, Inc. (NASDAQ:ACON) Stock Short Interest Report for September

Aclarion, Inc. (NASDAQ:ACON) was the target of a significant drop in short interest during the month of September. As of September 30th, there was short interest totaling 48,934 shares, a drop of 35.6% from the September 15th total of 76,007 shares. Based on an average daily trading volume, of 62,470 shares, the short-interest ratio is currently 0.8 days. Approximately 1.7% of the company’s shares are sold short.

Aclarion Stock Down 5.3%

Shares of NASDAQ:ACON opened at $1.85 on Friday. Aclarion has a twelve month low of $1.85 and a twelve month high of $9.36. The stock’s 50 day moving average is $2.44 and its 200-day moving average is $2.83. The firm has a market capitalization of $5.33 million, a price-to-earnings ratio of -0.25 and a beta of 1.20.

Aclarion (NASDAQ:ACON) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($1.12) EPS for the quarter, missing analysts’ consensus estimates of ($1.05) by ($0.07). Aclarion had a negative net margin of 10,948.81% and a negative return on equity of 59.34%. The business had revenue of $0.03 million for the quarter, compared to the consensus estimate of $0.03 million. Equities research analysts anticipate that Aclarion will post -4.51 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

ACON has been the subject of several research analyst reports. Weiss Ratings raised Aclarion from a “sell (e)” rating to a “sell (e+)” rating in a research report on Wednesday, August 5th. Wall Street Zen raised Aclarion from a “sell” rating to a “hold” rating in a research note on Saturday, June 20th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $7.50.

Insiders Place Their Bets

In other news, Director Ryan Bond bought 21,122 shares of the company’s stock in a transaction that occurred on Thursday, August 13th. The shares were acquired at an average price of $2.37 per share, for a total transaction of $50,059.14. Following the completion of the acquisition, the director directly owned 76,122 shares in the company, valued at approximately $180,409.14. This represents a 38.40% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Insiders have acquired a total of 51,863 shares of company stock worth $125,670 over the last ninety days. 0.01% of the stock is owned by company insiders.

About Aclarion

Aclarion, Inc (NASDAQ: ACON) is a healthcare technology company focused on improving the diagnosis and treatment planning of chronic low back pain. The company develops software designed to help physicians identify the spinal discs that may be contributing to a patient’s pain.

Its primary product, Nociscan, is a cloud-based platform that analyzes magnetic resonance spectroscopy data along with other imaging information. The system generates quantitative assessments, including Nociscores, intended to provide additional insight into disc health and support physicians in evaluating potential treatment options.

Aclarion’s technology is designed for use by spine specialists, radiologists, imaging centers and other healthcare providers.